ANG Lifesciences India Ltd
Incorporated in 2006, ANG Lifesciences India Ltd manufactures and markets finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials[1]
- Market Cap ₹ 62.6 Cr.
- Current Price ₹ 47.9
- High / Low ₹ 86.1 / 44.5
- Stock P/E
- Book Value ₹ 58.4
- Dividend Yield 0.00 %
- ROCE 1.29 %
- ROE -10.4 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.82 times its book value
Cons
- Company has low interest coverage ratio.
- Promoters have pledged 44.9% of their holding.
- Company has high debtors of 183 days.
- Working capital days have increased from 130 days to 198 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|
| 154 | 354 | 220 | 146 | 108 | |
| 140 | 286 | 205 | 136 | 107 | |
| Operating Profit | 14 | 68 | 15 | 10 | 1 |
| OPM % | 9% | 19% | 7% | 7% | 1% |
| 1 | 1 | 10 | -1 | -0 | |
| Interest | 4 | 9 | 12 | 11 | 11 |
| Depreciation | 1 | 6 | 9 | 8 | 8 |
| Profit before tax | 10 | 54 | 3 | -11 | -17 |
| Tax % | 31% | 25% | 110% | -5% | |
| 7 | 40 | -0 | -10 | -15 | |
| EPS in Rs | 5.26 | 31.02 | -0.20 | -7.77 | -11.47 |
| Dividend Payout % | 0% | 3% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| TTM: | -47% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -558% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | -35% |
| 1 Year: | -37% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -10% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Equity Capital | 10 | 13 | 13 | |
| Reserves | 73 | 73 | 63 | |
| 77 | 73 | 73 | ||
| 130 | 119 | 93 | ||
| Total Liabilities | 290 | 278 | 242 | |
| 93 | 88 | 58 | ||
| CWIP | 0 | 0 | 0 | |
| Investments | 0 | 0 | 0 | |
| 198 | 190 | 184 | ||
| Total Assets | 290 | 278 | 242 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 25 | 26 | -9 | ||
| -44 | -9 | 20 | ||
| 20 | -17 | -10 | ||
| Net Cash Flow | 0 | -0 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 105 | 138 | 183 | |
| Inventory Days | 59 | 118 | 183 | |
| Days Payable | 113 | 165 | 254 | |
| Cash Conversion Cycle | 51 | 91 | 112 | |
| Working Capital Days | 78 | 114 | 198 | |
| ROCE % | 9% | 1% |
Documents
Announcements
- Unaudited Standalone And Consolidated Financial Result For Quarter Ended As At 30.06.2024 14 Aug
- Board Meeting Outcome for Outcome Of Board Meeting Dated 14.08.2024 14 Aug
-
Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors
14 Aug - The Statutory Auditor has resigned from the company w.e.f. 14.08.2024. For your reference please find and attached herewith disclosure along with the resignation letter of …
- Board Meeting Intimation for Notice Of Board Meeting Under Reg. 29Of SEBI (LODR), 2015 7 Aug
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 17 Jul
Business Overview:[1][2]
Company manufactures and sells products like injections, tablets, capsules, syrups, ointments of different varieties. It deals in 4 market segments: institutional segment, third party manufacturing, direct marketing and export market. Apart from this, company is also providing printing & packing solutions especially in mono cartons, paper printing, corrugation, aluminiumfoils (blister foils)